Drug intelligence / Profile preview

SD-I01

Development stage: Preclinical
Lead developer: Sinedore Medicine
Modality: Small Molecules
Administration: Topical, Intratumoral, Intravenous

Overview

SD-I01 is a small molecule drug candidate being developed by Sinedore Medicine for the treatment of rare lung diseases. As of early 2024, the program is in the lead optimization and preclinical development stages. While the specific molecular target and biological pathway remain undisclosed by the developer, the drug is part of Sinedore's pipeline focusing on specialized therapeutic areas including metabolic and respiratory conditions.

Beyond the preview

Go deeper on SD-I01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SD-I01.

Explore the full profile